The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2020 | Reflections on the ADAURA study
Jared Weiss, MD, of UNC Lineberger, Chapel Hill, NC, discusses highlights on non-small cell lung cancer (NSCLC) presented at ASCO 2020. Dr Weiss reflects on data from the ADAURA study (NCT02511106) in which patients with stage IB–IIIA EGFR mutation positive NSCLC patients were treated with osimertinib as adjuvant therapy after complete tumor resection. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
